Khalid Al-Naamani

Dr. Khalid Al-Naamani

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
AWAiman Al Wahaibi
Aiman Al Wahaibi
KAKhalid Al-Naamani
Khalid Al-Naamani
AAAhmed Alkindi
Ahmed Alkindi
IQIssa Al Qarshoubi
Issa Al Qarshoubi
INTRODUCTION: Bile leak is a serious complication of hepatobiliary surgery. The incidence has remained the same over the last decade despite significant improvement in the results of liver surgery. PRESENTATION OF CASE: A 21-year-old man was a passenger in a motor vehicle and sustained a blunt abdominal trauma in a high-speed collision leading to major liver laceration. He had right lobe hepatectomy complicated by major bile leak. He was not fit for further surgery and he, therefore, had ERCP and obliteration of the leaking bile duct using a combination of metallic coil and N-butyl cyanoacrylate. DISCUSSION: Endoscopic therapy has become the modality of choice in the treatment of biliary tract injuries. Different modalities of management of persistent bile leak such as sphincterotomy, plastic biliary stents, and nasobiliary drainage have been described. Obliteration of bile duct leak using N-butyl cyanoacrylate and coil embolization has been described but most of these reports used the percutaneous transhepatic approach. CONCLUSION: In this paper, we describe the second reported case in English literature of a novel endoscopic technique using a combination of metallic coil embolization and N-butyl cyanoacrylate in a patient with major bile leak who was not a candidate for surgery as well as a third report of the late complication of coil migration to the common bile duct.

Verified
Journal Article
Open access
PDF file
AAAbdullah M Al Alawi
Abdullah M Al Alawi
HSHalima H. Al Shuaili
Halima H. Al Shuaili
KAKhalid Al-Naamani
Khalid Al-Naamani
ZAZakariya Rashid AL-Naamani
Zakariya Rashid AL-Naamani
Said A. Al-BusafiSaid A. Al-Busafi
Said A. Al-Busafi
Background: Chronic hepatitis C (HCV) infection presents global health challenges with significant morbidity and mortality implications. Successfully treating patients with cirrhosis may lead to mortality rates comparable to the general population. This study aims to utilize machine learning techniques to create predictive mortality models for individuals with chronic HCV infections. Methods: Data from chronic HCV patients at Sultan Qaboos University Hospital (2009–2017) underwent analysis. Data pre-processing handled missing values and scaled features using Python via Anaconda. Model training involved SelectKBest feature selection and algorithms such as logistic regression, random forest, gradient boosting, and SVM. The evaluation included diverse metrics, with 5-fold cross-validation, ensuring consistent performance assessment. Results: A cohort of 702 patients meeting the eligibility criteria, predominantly male, with a median age of 47, was analyzed across a follow-up period of 97.4 months. Survival probabilities at 12, 36, and 120 months were 90.0%, 84.0%, and 73.0%, respectively. Ten key features selected for mortality prediction included hemoglobin levels, alanine aminotransferase, comorbidities, HCV genotype, coinfections, follow-up duration, and treatment response. Machine learning models, including the logistic regression, random forest, gradient boosting, and support vector machine models, showed high discriminatory power, with logistic regression consistently achieving an AUC value of 0.929. Factors associated with increased mortality risk included cardiovascular diseases, coinfections, and failure to achieve a SVR, while lower ALT levels and specific HCV genotypes were linked to better survival outcomes. Conclusions: This study presents the use of machine learning models to predict mortality in chronic HCV patients, providing crucial insights for risk assessment and tailored treatments. Further validation and refinement of these models are essential to enhance their clinical utility, optimize patient care, and improve outcomes for individuals with chronic HCV infections.

8 September 2025 in Liver International
Verified
Journal Article
Closed access
ZYZobair M. Younossi
Zobair M. Younossi
JPJames M. Paik
James M. Paik
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
MKMustafa Kanat
Mustafa Kanat
MEMohamed El-Kassas
Mohamed El-Kassas
SASaleh AlQahtani
Saleh AlQahtani

5 May 2014 in Helicobacter
Verified
Journal Article
Closed access
PDF file
SASiham Al‐Sinani
Siham Al‐Sinani
SSSharef W. Sharef
Sharef W. Sharef
KAKhalid Al-Naamani
Khalid Al-Naamani
HAHyatt Al‐Sharji
Hyatt Al‐Sharji

23 May 2025 in Liver International
Verified
Journal Article
Closed access
MEMohamed El-Kassas
Mohamed El-Kassas
MVMarcela Villota‐Rivas
Marcela Villota‐Rivas
KAKhalid A Alswat
Khalid A Alswat
KAKhalid Al-Naamani
Khalid Al-Naamani
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
TCthe Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA) Collaborators
the Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA) Collaborators

15 September 2021 in Journal of Infection and Public Health
Verified
Journal Article
Open access
KAKhalid Al-Naamani
Khalid Al-Naamani
IAIssa Al-Jahdhami
Issa Al-Jahdhami
WAWafa Al-Tamtami
Wafa Al-Tamtami
KAKawther Al-Amri
Kawther Al-Amri
Murtadha Al-KhaboriMurtadha Al-Khabori
Murtadha Al-Khabori
JAJuhaina AlWahaibi
Juhaina AlWahaibi
The primary objective is to determine the prevalence of SARS-CoV-2 antibodies persistence among HCWs and specifically among asymptomatic HCWs. A secondary objective is to determine the duration of persistent SARS-CoV-2 antibodies post infection and factors affecting this duration. The findings are expected to open the door for further research into the role of SARS-CoV-2 antibodies during the current COVID-19 pandemic. HCWs were divided into high, intermediate, and low risk based on their type and location of work. All participants filled a questionnaire. Blood samples were obtained for SARS-CoV-2 IgG/total antibodies. A documented SARS-CoV-2 PCR or Anti-SARS-CoV-2 IgG/total antibodies defined the primary outcome. The probability of persistence of antibody was calculated using the Kaplan–Meier estimator. Logistic and Cox regression were used where appropriate. A total of 1111 HCWs were included. The median age 37 years (IQR: 31–43). More than half (67.2%) were females. The primary outcome was seen in 373 (33.6%) participants with a median age of 36 years (IQR: 29–41). Only 37.2% of those with documented positive SARS-CoV-2 PCR had reactive serology, while only 16.2% of those with reactive serology had documented positive SARS-CoV-2 PCR. Male gender (OR 0.44, P < 0.001) and older age (OR 0.98, P < 0.019) were associated with a lower risk of acquiring SARS-CoV-2 infection. The probability of persistent SARS-CoV-2 antibodies at six months was 60.2% (95% CI: 49.5%–73.1%). Omanis had a higher probability of losing the antibody than others (HR 2.63, P = 0.021). We report a high prevalence of anti-SARS-CoV-2 antibodies among HCWs in Oman, specifically among asymptomatic HCWs. Community was the most likely source of infection. Therefore, the society must adhere to the roles and regulations set to reduce the risk of transmission. We demonstrate a high percentage of seroconversion post initial infection, and the persistence of SARS-CoV-2 antibodies at six months in more than half of those previously infected. We demonstrated a new interesting finding of fast decline of SARS-CoV2 antibody levels over time among different nationalities and this requires further research.